First, antigen‐targeted CAR‐T infiltrating tumor lesions to locally secrete PD‐L1‐targeting Nb‐BiTE would be more effective with fewer safety concerns than systemic administration of PD‐L1 blockade antibodies.[31] Second, the secreted BiTE could recruit bystander effectors and the CD3ε‐targeted Nb moiety of BiTE could further activate these effector cells to synergize with Nb‐CAR‐γδT cells against PD‐L1‐expressing tumor cells. The gene discussed is CD274; the disease is neoplasm.